Health Care · Pharmaceutical Preparations · Nasdaq · CIK 907654 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $88.07Day −2.63%Mkt cap $5.3B1Y +541.4%Off 52W high −9.9%Vol (1Y) 78.3%
Daily closing price, split-adjusted to the current basis; 1.9y shown of 467 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest14.6% of sh out |
| Days to cover6.2d |
| 13F net flow (QoQ)+3.38% |
| Top-10 13F concentration59.3% |
| Next report (est.)2026-08-01 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$116.3M |
| ROE−24.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+190.6% |
| 1Y+541.4% |
| Since incept. (ann.)+92.0% |
Total return through 2026-07-29 · series begins 2024-09-03. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)78.3% |
| Ann. volatility (3Y)79.2% |
| Sharpe (1Y)2.83 |
| Sharpe (3Y)1.24 |
| Max drawdown (1Y)−24.7% |
| Max drawdown (3Y)−77.8% |
| Beta (3Y vs SPY)0.13 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 7.4M | $365M | 15.00% | +2.3% |
| Venrock Adviser, LLC | 4.1M | $203M | 8.37% | +0.0% |
| Fairmount Funds Management LLC | 3.7M | $182M | 7.48% | +0.0% |
| BlackRock, Inc. | 3.5M | $173M | 7.12% | −0.3% |
| VIKING GLOBAL INVESTORS LP | 2.7M | $131M | 5.38% | +0.0% |
| Paradigm Biocapital Advisors LP | 2.3M | $114M | 4.68% | +35.7% |
| RTW INVESTMENTS, LP | 2.1M | $101M | 4.15% | +0.0% |
| Deep Track Capital, LP | 2.0M | $100M | 4.11% | −5.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 106.8% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 6,992,310 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2025-06-30 | 2025-08-11 | −$0.46 | — | — | — |
| 2025-03-31 | 2025-05-14 | −$0.40 | — | — | — |
| 2024-09-30 | 2024-11-13 | −$1.46 | — | — | — |
| 2024-06-30 | 2024-08-01 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-01 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
